Medexus Pharmaceuticals Inc (TSE:MDP) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Medexus Pharmaceuticals announces that the FDA has accepted for review the resubmission of their New Drug Application for treosulfan, expecting a decision by October 30, 2024. Treosulfan, already successful in Canada, could significantly impact Medexus’s revenue if approved in the US. The company remains optimistic about treosulfan’s approval and its potential in the US market, reflecting its strong performance as a treatment in Europe and Canada.
For further insights into TSE:MDP stock, check out TipRanks’ Stock Analysis page.